MOREPENLABPharmaceuticals
Morepen Laboratories Ltd — Profit & Loss Statement
₹33.68
-2.22%
Morepen Laboratories Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Tax Rate For Calcs | 0.24 | 0.29 | 0.31 | 0.20 | — |
| Normalized EBITDA | 192.43 Cr | 172.60 Cr | 85.67 Cr | 156.77 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 118.02 Cr | 96.16 Cr | 38.68 Cr | 101.68 Cr | — |
| Reconciled Depreciation | 28.98 Cr | 33.47 Cr | 27.93 Cr | 27.64 Cr | — |
| Reconciled Cost Of Revenue | 1.16K Cr | 1.06K Cr | 970.37 Cr | 1.06K Cr | — |
| EBITDA | 192.43 Cr | 172.60 Cr | 85.67 Cr | 156.77 Cr | — |
| EBIT | 163.45 Cr | 139.13 Cr | 57.74 Cr | 129.13 Cr | — |
| Net Interest Income | -8.34 Cr | -3.71 Cr | -0.32 Cr | -1.10 Cr | — |
| Interest Expense | 8.34 Cr | 3.71 Cr | 1.98 Cr | 2.43 Cr | — |
| Normalized Income | 118.02 Cr | 96.16 Cr | 38.68 Cr | 101.68 Cr | — |
| Net Income From Continuing And Discontinued Operation | 118.02 Cr | 96.16 Cr | 38.68 Cr | 101.68 Cr | — |
| Total Expenses | 1.67K Cr | 1.57K Cr | 1.36K Cr | 1.43K Cr | — |
| Diluted Average Shares | 53.65 Cr | 51.15 Cr | 50.22 Cr | 51.98 Cr | — |
| Basic Average Shares | 53.65 Cr | 51.15 Cr | 50.22 Cr | 45.00 Cr | — |
| Diluted EPS | 2.20 | 1.88 | 0.77 | 1.96 | — |
| Basic EPS | 2.20 | 1.88 | 0.77 | 2.26 | — |
| Diluted NI Availto Com Stockholders | 118.02 Cr | 96.16 Cr | 38.68 Cr | 101.68 Cr | — |
| Net Income Common Stockholders | 118.02 Cr | 96.16 Cr | 38.68 Cr | 101.68 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 118.02 Cr | 96.16 Cr | 38.68 Cr | 101.68 Cr | — |
| Minority Interests | 50000.00 | -0.46 Cr | -3000.00 | 14000.00 | — |
| Net Income Including Noncontrolling Interests | 118.02 Cr | 96.62 Cr | 38.68 Cr | 101.68 Cr | — |
| Net Income Continuous Operations | 118.02 Cr | 96.62 Cr | 38.68 Cr | 101.68 Cr | — |
| Tax Provision | 37.09 Cr | 38.80 Cr | 17.08 Cr | 25.02 Cr | — |
| Pretax Income | 155.11 Cr | 135.42 Cr | 55.76 Cr | 126.70 Cr | — |
| Other Non Operating Income Expenses | 18.36 Cr | 13.97 Cr | 4.48 Cr | 8.98 Cr | — |
| Net Non Operating Interest Income Expense | -8.34 Cr | -3.71 Cr | -0.32 Cr | -1.10 Cr | — |
| Interest Expense Non Operating | 8.34 Cr | 3.71 Cr | 1.98 Cr | 2.43 Cr | — |
| Operating Income | 145.09 Cr | 125.16 Cr | 51.60 Cr | 109.03 Cr | — |
| Operating Expense | 507.18 Cr | 502.85 Cr | 391.98 Cr | 371.60 Cr | — |
| Other Operating Expenses | 189.30 Cr | 177.94 Cr | 91.96 Cr | 106.02 Cr | — |
| Depreciation And Amortization In Income Statement | 28.98 Cr | 33.47 Cr | 27.93 Cr | 27.64 Cr | — |
| Depreciation Income Statement | 28.98 Cr | 33.47 Cr | 27.93 Cr | 27.64 Cr | — |
| Selling General And Administration | 79.99 Cr | 109.98 Cr | 107.18 Cr | 67.76 Cr | — |
| Selling And Marketing Expense | 79.99 Cr | 109.98 Cr | 93.01 Cr | 53.58 Cr | — |
| Gross Profit | 652.27 Cr | 628.01 Cr | 443.58 Cr | 480.63 Cr | — |
| Cost Of Revenue | 1.16K Cr | 1.06K Cr | 970.37 Cr | 1.06K Cr | — |
| Total Revenue | 1.81K Cr | 1.69K Cr | 1.41K Cr | 1.54K Cr | — |
| Operating Revenue | 1.81K Cr | 1.69K Cr | 1.41K Cr | 1.54K Cr | — |
| Interest Income | — | 2.50 Cr | 1.66 Cr | 1.33 Cr | 2.13 Cr |
| Rent Expense Supplemental | — | 12.08 Cr | 10.74 Cr | 8.18 Cr | 5.14 Cr |
| Interest Income Non Operating | — | 2.50 Cr | 1.66 Cr | 1.33 Cr | 2.13 Cr |
| Research And Development | — | 5.20 Cr | 3.07 Cr | 3.01 Cr | 5.65 Cr |
| General And Administrative Expense | — | 17.34 Cr | 14.16 Cr | 14.19 Cr | 12.17 Cr |
| Rent And Landing Fees | — | 12.08 Cr | 10.74 Cr | 8.18 Cr | 5.14 Cr |
| Total Other Finance Cost | — | — | — | — | 0.49 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Morepen Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.